Evidence map›Paper›PMID 28082441›Full record

ArticleBlood2017

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

Simon Mantha, Debra A Goldman, Sean M Devlin, Ju-Whei Lee, Diana Zannino, Marnie Collins, Dan Douer, Harry J Iland, Mark R Litzow, Eytan M Stein and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Predictors of Early Death in Acute Promyelocytic Leukemia.Medical sciences (Basel, Switzerland) · 2025
    Review
  6. Article
  7. Review
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Hemorrhage in acute promyelocytic leukemia-fibrinolysis in focus.Research and practice in thrombosis and haemostasis · 2024
    Review
  15. Dysregulated hemostasis in acute promyelocytic leukemia.International journal of hematology · 2024
    Review
  16. Article
  17. How to avoid early mortality in acute promyelocytic leukemia.Hematology. American Society of Hematology. Education Program · 2023
    Article
  18. Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia.medRxiv : the preprint server for health sciences · 2023
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 3 countries.

Simon ManthaDepartment of Medicine, Hematology Service, and.
Debra A GoldmanDepartment of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Sean M DevlinDepartment of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Ju-Whei LeeDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Biostatistics Center, Boston, MA.
Diana ZanninoCentre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Center, East Melbourne, Australia.
Marnie CollinsCentre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Center, East Melbourne, Australia.
Dan DouerDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Harry J IlandInstitute of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia.
Mark R LitzowDepartment of Hematology, Mayo Clinic, Rochester, MN.
Eytan M SteinDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Frederick R AppelbaumClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Richard A LarsonSection of Hematology/Oncology, University of Chicago, Chicago, IL.
Richard StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Bayard L PowellSection on Hematology and Oncology, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC.
Susan GeyerHealth Informatics Institute, University of South Florida, Tampa, FL.
Kristina LaumannDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Jacob M RoweDepartment of Hematology, Rambam Medical Center, Haifa, Israel.
Harry ErbaDivision of Hematology and Oncology, University of Alabama School of Medicine, Birmingham, AL.
Steven CoutreDivision of Hematology, Stanford University School of Medicine, Stanford, CA.
Megan OthusPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.
Jae H ParkDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Peter H WiernikCancer Research Foundation, Chappaqua, NY.
Martin S TallmanDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Memorial Sloan Kettering Cancer Center · USFred Hutch Cancer Center · USPeter MacCallum Cancer Centre · AUDana-Farber Cancer Institute · USEastern Cooperative Oncology Group · USKids' Brain Tumor Cure Foundation · USMayo Clinic · USMayo Clinic in Arizona · USRambam Health Care Campus · ILRoyal Prince Alfred Hospital · AUStanford University · USUniversity of Alabama at Birmingham · USUniversity of Chicago · USUniversity of South Florida · USWake Forest Baptist Comprehensive Cancer Center

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2M
Statistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareU10CA180867 · NCI · DANA-FARBER CANCER INST · PI BURSTEIN, HAROLD JOHN, KIBEL, ADAM S · 2014 to 2018
$6.2M
UM LAPs- U10 GrantU10CA180801 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZALUPSKI, MARK M · 2014 to 2018
$3.7M
NCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180801NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180888
6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is commonly complicated by a complex coagulopathy. Uncertainty remains as to which markers of bleeding risk are independent predictors. Drawing from 5 large clinical trials that included all-

Indexed as

Clinical Trials as TopicCohort StudiesHemorrhageHumansInduction ChemotherapyLeukemia, Promyelocytic, AcuteLeukocyte CountMultivariate AnalysisPrognosisTretinoinTretinoin

Identifiers

PMID28082441
PMCPMC5374291
OpenAlexW2559236277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.